Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands
Authors
Keywords
-
Journal
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
Volume 40, Issue 3, Pages 605-613
Publisher
Wiley
Online
2017-12-24
DOI
10.1002/hed.25035
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma
- (2017) Wim van Boxtel et al. ORAL ONCOLOGY
- Combination chemotherapy of carboplatin and paclitaxel for advanced/metastatic salivary gland carcinoma patients: differences in responses by different pathological diagnoses
- (2016) Kenji Nakano et al. ACTA OTO-LARYNGOLOGICA
- A 20-Year Review of 75 Cases of Salivary Duct Carcinoma
- (2016) Mark R. Gilbert et al. JAMA Otolaryngology-Head & Neck Surgery
- Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer
- (2015) Jack Schalken et al. BJU INTERNATIONAL
- Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
- (2015) Paul L. Nguyen et al. EUROPEAN UROLOGY
- Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers
- (2015) Laura D. Locati et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma
- (2014) Tatsuo Masubuchi et al. International Journal of Clinical Oncology
- Trastuzumab for the Treatment of Salivary Duct Carcinoma
- (2013) S. A. Limaye et al. ONCOLOGIST
- Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient Treatment
- (2012) V. Nardi et al. CLINICAL CANCER RESEARCH
- Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes*
- (2012) Silvana Di Palma et al. HISTOPATHOLOGY
- Androgen Receptor–Positive Salivary Duct Carcinoma: A Disease Entity With Promising New Treatment Options
- (2011) Heidy C.J. Jaspers et al. JOURNAL OF CLINICAL ONCOLOGY
- Salivary Duct Carcinoma: Targeting the Phosphatidylinositol 3-Kinase Pathway by Blocking Mammalian Target of Rapamycin With Temsirolimus
- (2011) Sarina A. Piha-Paul et al. JOURNAL OF CLINICAL ONCOLOGY
- Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas
- (2011) Till Sebastian Clauditz et al. PATHOLOGY
- Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs)
- (2009) Laura D. Locati et al. ORAL ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search